MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| SIEGEL JAY PHILIP | Director | May 20 '24 | Option Exercise | 0.00 | 4,500 | 0 | 4,500 | May 22 04:34 PM | | HEIDEN WILLIAM K | Director | May 20 '24 | Option Exercise | 0.00 | 4,500 | 0 | 4,500 | May 22 04:34 PM | | Jackson Scott Thomas | Director | May 20 '24 | Option Exercise | 0.00 | 4,500 | 0 | 4,500 | May 22 04:34 PM | | STUMP DAVID C | Director | May 20 '24 | Option Exercise | 0.00 | 4,500 | 0 | 4,500 | May 22 04:33 PM | | O'Brien Federica F. | Director | May 20 '24 | Option Exercise | 0.00 | 4,500 | 0 | 4,500 | May 22 04:33 PM | | Liu Margaret | Director | May 20 '24 | Option Exercise | 0.00 | 4,500 | 0 | 4,500 | May 22 04:33 PM | | Chhabra Meenu | Director | May 20 '24 | Option Exercise | 0.00 | 4,500 | 0 | 4,500 | May 22 04:33 PM | | Ferrante Karen Jean | Director | May 20 '24 | Option Exercise | 0.00 | 4,500 | 0 | 4,500 | May 22 04:32 PM | | HURWITZ EDWARD | Director | May 20 '24 | Option Exercise | 0.00 | 4,500 | 0 | 37,574 | May 22 04:32 PM | | Peters Jeffrey Stuart | Senior VP and General Counsel | Apr 04 '24 | Option Exercise | 4.82 | 42,500 | 204,850 | 51,395 | Apr 08 06:07 PM | | Peters Jeffrey Stuart | Senior VP and General Counsel | Apr 04 '24 | Sale | 15.55 | 51,395 | 799,148 | 0 | Apr 08 06:07 PM | | Peters Jeffrey Stuart | Senior VP and General Counsel | Mar 06 '24 | Option Exercise | 10.90 | 19,625 | 213,875 | 28,520 | Mar 08 04:14 PM | | Peters Jeffrey Stuart | Senior VP and General Counsel | Mar 06 '24 | Sale | 21.50 | 19,625 | 421,938 | 8,895 | Mar 08 04:14 PM | | Risser Eric Blasius | Chief Operating Officer | Mar 04 '24 | Option Exercise | 10.15 | 15,000 | 152,250 | 80,059 | Mar 06 04:20 PM | | Risser Eric Blasius | Chief Operating Officer | Mar 04 '24 | Sale | 19.76 | 41,159 | 813,501 | 38,900 | Mar 06 04:20 PM | | Spitznagel Thomas | Sr VP, Technical Ops | Mar 04 '24 | Option Exercise | 11.50 | 10,000 | 115,000 | 18,316 | Mar 06 04:19 PM | | Spitznagel Thomas | Sr VP, Technical Ops | Mar 04 '24 | Sale | 20.00 | 10,000 | 200,000 | 8,316 | Mar 06 04:19 PM | | Karrels James | SVP, CFO and Secretary | Mar 04 '24 | Sale | 20.50 | 30,000 | 615,000 | 171,452 | Mar 06 04:18 PM | | Peters Jeffrey Stuart | Senior VP and General Counsel | Feb 26 '24 | Sale | 17.22 | 16,124 | 277,655 | 8,895 | Feb 28 04:20 PM | | Peters Jeffrey Stuart | Senior VP and General Counsel | Feb 22 '24 | Option Exercise | 0.00 | 26,250 | 0 | 35,145 | Feb 26 04:27 PM | | Bonvini Ezio | Sr VP, Research & CSO | Feb 22 '24 | Option Exercise | 0.00 | 28,125 | 0 | 110,258 | Feb 26 04:26 PM | | Eck Stephen L. | Chief Medical Officer | Feb 15 '24 | Option Exercise | 0.00 | 16,670 | 0 | 16,670 | Feb 20 06:41 PM | | Peters Jeffrey Stuart | Senior VP and General Counsel | Feb 15 '24 | Option Exercise | 0.00 | 13,336 | 0 | 13,336 | Feb 20 06:05 PM | | Koenig Scott | President and CEO | Feb 15 '24 | Option Exercise | 0.00 | 42,341 | 0 | 1,091,977 | Feb 20 06:04 PM | | Cilinski Lynn | VP, Controller and Treasurer | Feb 15 '24 | Option Exercise | 0.00 | 6,668 | 0 | 8,591 | Feb 20 06:04 PM | | Risser Eric Blasius | Chief Operating Officer | Feb 15 '24 | Option Exercise | 0.00 | 16,670 | 0 | 70,938 | Feb 20 06:04 PM | | Karrels James | SVP, CFO and Secretary | Feb 15 '24 | Option Exercise | 0.00 | 15,003 | 0 | 206,779 | Feb 20 06:04 PM | | Spitznagel Thomas | Sr VP, Technical Ops | Feb 15 '24 | Option Exercise | 0.00 | 13,336 | 0 | 13,336 | Feb 20 06:03 PM | | Bonvini Ezio | Sr VP, Research & CSO | Feb 15 '24 | Option Exercise | 0.00 | 16,670 | 0 | 88,004 | Feb 20 06:03 PM | | Bonvini Ezio | Sr VP, Research & CSO | Feb 07 '24 | Sale | 18.00 | 3,334 | 60,012 | 71,334 | Feb 07 04:19 PM | | Peters Jeffrey Stuart | Senior VP and General Counsel | Feb 05 '24 | Option Exercise | 11.11 | 76,251 | 847,355 | 76,251 | Feb 07 04:17 PM | | Peters Jeffrey Stuart | Senior VP and General Counsel | Feb 05 '24 | Sale | 16.50 | 76,251 | 1,258,142 | 0 | Feb 07 04:17 PM | | Bonvini Ezio | Sr VP, Research & CSO | Feb 01 '24 | Sale | 15.00 | 13,316 | 199,740 | 74,668 | Feb 02 04:21 PM | | Bonvini Ezio | Sr VP, Research & CSO | Jan 19 '24 | Sale | 12.00 | 13,316 | 159,792 | 87,984 | Jan 22 04:57 PM | | Bonvini Ezio | Sr VP, Research & CSO | Dec 20 '23 | Sale | 10.08 | 18,880 | 190,310 | 101,300 | Dec 21 04:12 PM |
|
